

# DRUG DISCOVERY & DEVELOPMENT

FEBRUARY 24, 2021

Date	Time	Track	Presentation Title	Speaker
24-Feb	06:00 - 07:00 AM	Novel Advancements to Clinical Development	Fueling Discovery: Next-generation isolation of PBMCs and primary cells from Miltenyi Biotec	Josh Mahlios, PhD Senior Marketing Product Manager, Miltenyi Biotec
24-Feb	06:00 - 07:00 AM		Introducing GenScript's DNA-Encoded Chemical Library Kit - GenDECL	Rouba Najjar, MBA Head of US Marketing and Business Development, Products Division
24-Feb	07:30 - 08:30 AM	Innovative Biomarkers in Drug Development	Keynote Presentation: The biomarker to companion diagnostic continuum: a road map for the delivery of precision medicine	Steven M. Anderson, PhD Chief Scientific Officer, Covance Drug Development
24-Feb	09:00 - 10:00 AM	Innovative Biomarkers in Drug Development	Keynote Panel Presentation: Biomarker assays - bioanalytical meets CLIA	Roger Hayes, PhD Vice President, Bioanalytical Services, ICON Laboratory Services Andrew Roche, PhD Senior Director, Scientific Affairs, ICON Laboratory Services
24-Feb	10:30 - 11:30 AM		The New xMAP® INTELLIFLEX: Technology You Trust. Versatility You Want	Sherry A. Dunbar, PhD, MBA Senior Director, Global Scientific Affairs Josh Jenkins, MS Sales Development Manager, Licensed Technologies Group, Luminex Corporation
24-Feb	10:30 - 11:30 AM	New Practices in Early Phase Drug Discovery	The Visiopharm Platform: Flexible tools to solve real-world problems	Keith Bowers, PhD Senior Business Development Manager, OracleBio Dave Mason, PhD Technical Sales Specialist, Visiopharm

24-Feb	12:00 - 01:00 PM	New Practices in Early Phase Drug Discovery	Deep Mechanistic profiling of immune oncology drug combinations in cancer patients with CIVO intratumoral micro-dosing and NanoString's GeoMx® Digital Spatial Profiler	Jason Frazier Director of Scientific Operations, Presage Biosciences Sarah Warren, PhD Sr Director of Translational Science, NanoString Technologies
24-Feb	12:00 - 01:00 PM	New Practices in Early Phase Drug Discovery	Speed up your drug discovery with ready-to-use stable cell lines	Vevian Zhang Product Manager, GenScript
24-Feb	01:30 - 02:30 PM	New Practices in Early Phase Drug Discovery	Roundtable Panel Presentation: Recent Trends in Screening GPCRs	Annette Gilchrist, PhD Associate-Professor, Pharmaceutical Sciences, Midwestern University Professor Kevin Pflieger, MA, PhD, FBPhS Director, Biomedical and Health Innovation, The University of Western Australia and WA Life Sciences Innovation Hub; President, Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT); Head, Molecular Endocrinology and Pharmacology, Harry Perkins Institute of Medical Research (Centre for Medical Research, The University of Western Australia); Deputy Director & UWA Node Leader, ARC Centre for Personalised Therapeutics Technologies Juan José Fung, PhD Principal Scientist, GPCR Therapeutics Aarti Kawatkar Sr. Scientist, Chemical Biology and Proteomics group, AstraZeneca Yamina A. Berchiche, PhD Founder, Dr. GPCR Ajay Yekkirala, PhD Co-Founder & CSO, Blue Therapeutics
24-Feb	03:00 - 04:00 PM	New Practices in Early Phase Drug Discovery	PROTACs: A Chemistry Journey of Protein Degraders	Jie Jack Li, PhD Vice President, Discovery Chemistry at ChemPartner
24-Feb	03:00 - 04:00 PM	Innovative Biomarkers in Drug Development	Supporting Biomarker Discovery One Cell at a Time - Single cell analysis solutions that drive results and insights	Leif Schauer, PhD Director, Global Product Management, QIAGEN Joseph Pearson, PhD Global Product Manager, QIAGEN Digital Insights
24-Feb	04:30 - 05:30 PM		Novel Solutions for High Throughput Antibody and Protein Purification Using Magnetic Beads Platform	Nishant Saxena, PhD Product Manager, GenScript

24-Feb	12:00 - 12:45 AM	Modern Approaches to Discovery, Preclinical and Clinical Lab Operations in COVID-19 Age	COVID's Impact on Life Sciences Recruiting	Don Alexander, CPC, CFP® President and Managing Director, GeneCoda
24-Feb	12:00 - 12:45 AM	Novel Advancements to Clinical Development	Evolution of a Platform-Based Non-Clinical Safety Assessment Approach for Vaccines	Joseph J. Senn, PhD, DABT Vice President, Nonclinical Sciences, Moderna
24-Feb	12:00 - 12:45 AM	Innovative Biomarkers in Drug Development	Lipidomics and Lipidomics in Research	Dr. Christian Klose CTO, Lipotype GmbH
24-Feb	12:00 - 12:45 AM	Innovative Biomarkers in Drug Development	Multi-diagnostic approaches for patient selection in immuno-oncology	Cindy Spittle VP Scientific Affairs, ICON Laboratory Services
24-Feb	12:00 - 12:45 AM	(3) Modern Approaches to Discovery, Preclinical, and Clinical Lab Operations in the COVID-19 Age	Nonclinical COVID-19 Vaccine Development During a Pandemic	Cynthia Rohde, PhD, DABT Associate Research Fellow, Drug Safety Research and Development, Pfizer, Inc.
24-Feb	12:00 - 12:45 AM	New Practices in Early Phase Drug Discovery	Preclinical evaluation of novel OT-analogs for the potential treatment of social behavioral deficits	Marsha Pierce, PhD Assistant Professor, Department of Pharmacology, Midwestern University
24-Feb	12:00 - 12:45 AM	Novel Advancements to Clinical Development	The Comprehensive A.I.-Driven Genomic Landscape for ALS - Implications for Drug Discovery and Development	Mark Kiel, MD, PhD Co-Founder and Chief Science Officer, Genomenon
24-Feb	12:00 - 12:45 AM	New Practices in Early Phase Drug Discovery	The development and application of TRUPATH biosensors to the study of GPCR pharmacology and functional selectivity	Reid Olsen, PhD, Pharmacology, Head of GPCR Pharmacology Exscientia Ltd